Table 1. Demographics and Participant Characteristics

| Total (N=73)           |   | HC (n=43)  | cMDD (n=30) |                            |
|------------------------|---|------------|-------------|----------------------------|
|                        |   | n (%)      | n (%)       | t-test/chi-square          |
| Sex                    | % Female  | 29 (67.4%) | 24 (80.0%)  | $x^2(1) = 1.40, p = .237$  |
| Gender                 | Female  | 28 (65.1%) | 21 (70.0%)  | $x^2(2) = 2.23, p = .328$  |
|                        | Male  | 14 (32.6%) | 6 (20.0%)   | -                          |
|                        | Something else (gender-fluid, non-binary, two-spirit, etc.) | 1 (2.3%)   | 3 (10.0%)   | -                          |
| Age (Years)            | M (SD)  | 27.0 (8.9) | 27.7 (8.7)  | t(71) = -0.35, p = .730    |
|                        | Range (years)   | 18-52      | 19-57       | -                          |
| Education              | Some college or associate degree                            | 17 (39.5%) | 11 (36.7%)  | $x^2(2) = 0.34, p = .844$  |
|                        | Bachelor's degree   | 13 (30.2%) | 8 (26.7%)   | -                          |
|                        | Graduate or professional training                           | 13 (30.2%) | 11 (36.7%)  | -                          |
| Ethnicity              | Hispanic/Latine   | 9 (20.9%)  | 7 (23.3%)   | $x^2(1) = 0.06, p = .807$  |
| Race                   | White   | 22 (51.2%) | 16 (53.3%)  | $x^2(1) = 0.03, p = .855$  |
|                        | Non-White   | 21 (48.8%) | 14 (46.7%)  | -                          |
|                        | Asian   | 9 (20.9)   | 5 (16.1%)   | -                          |
|                        | Black or African American                                   | 4 (9.3%)   | 5 (16.1%)   | -                          |
|                        | More than one race/unknown                                  | 8 (18.6%)  | 4 (12.9%)   | -                          |
| Medication             | SSRI  | 2 (4.7%)   | 4 (13.3%)   | $x^2(4) = 9.64, p = .047$  |
|                        | SNRI  | 0 (0%)     | 2 (6.7%)    | -                          |
|                        | NDRI  | 0 (0%)     | 4 (13.3%)   | -                          |
|                        | Benzodiazepine  | 0 (0%)     | 2 (6.7%)    | -                          |
|                        | Other psychotropic  | 0 (0%)     | 1 (3.3%)    | -                          |
| Number of Medications  | 0   | 41 (95.3%) | 20 (66.7%)  | $x^2(2) = 12.27, p = .002$ |
|                        | 1   | 2 (4.7%)   | 7 (23.3%)   | -                          |
|                        | 2   | 0 (0%)     | 3 (10.0%)   | -                          |
| IDAS-II Subscale Score | s M (SD)  |            |             | -                          |
|                        | Well-being  | 25.5 (6.8) | 17.3 (6.2)  | t(71) = 5.28, p < .001     |
|                        | General depression  | 31 (8.1)   | 61.8 (10.7) | t(69) = -13.72, p < .001   |

*Note.* Values reflect original IDAS-II Well-being scores. For analyses, anhedonia was reverse-coded (Well-being multiplied by -1) and standardized (z-scored).

**Table 2.** Trail-Making Task (TMT) Accuracy: Healthy Control and cMDD Resting-State MRI Results

| Effect             | Network | ROI 1 | ROI 2  | T Statistic (df) | p-unc |
|--------------------|---------|-------|--------|------------------|-------|
| TMT Accuracy: HC   | DAN     | R IPS | L IPS  | 2.52 (40)        | 0.016 |
|                    | SN      | ACC   | R RPFC | 2.03 (40)        | 0.049 |
| TMT Accuracy: cMDD | DAN-SN  | R FEF | R SMG  | 3.20 (28)        | 0.003 |
|                    | DAN     | R IPS | R FEF  | 2.44 (28)        | 0.021 |
|                    | DAN     | L IPS | R FEF  | 2.40 (28)        | 0.023 |
|                    | SN-FPN  | ACC   | R LPFC | 2.12 (28)        | 0.043 |